Ancillary and post-trial care
For all patients in the prophylactic arm, treatment ends after the 12th cycle of maintenance therapy (EOT). For all patients randomized to the MRD-triggered arm, who did not cross-over in the prophylactic arm, treatment ends after the 2nd cycle of consolidation therapy (EOT). After EOT patients are routinely followed-up and treated as per the standard of care at the discretion of the treating physician. The period of observation (and the overall study) ends for all patients when the last patient being included and alive has been followed for at least 730 days (2 years) counted from this patient’s day 1 (EOS).